Will Late Loss Debate Stifle Device Start-Up Innovation?
This article was originally published in Start Up
Executive Summary
The failure of Medtronic's Endeavor stent to hit its primary clinical trial endpoint has again spurred debate over surrogate endpoints, a potentially big issue for small companies.
You may also be interested in...
The Double-edged Sword of Diabetes Drug Development
Intense interest in new diabetes drugs gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk.
View From the Cath Lab: Hot Issues in Cardiology
Three leading interventional cardiologists provide international perspectives on the most important issues confronting their specialty and how they will impact the device industry.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.